

Immune Repertoire Sequencing Market by Product (Instrument, Software, Assay Kit & Reagent (TCR, BCR Kit)), Technology (Sequencing, Bioinformatics), Service (Data Analysis), Application (Research, Drug Discovery & Development) - Global Forecast to 2030

https://marketpublishers.com/r/I5FD02B1951EEN.html

Date: April 2025

Pages: 371

Price: US\$ 4,950.00 (Single User License)

ID: I5FD02B1951EEN

Abstracts

The global IRS market is projected to reach USD 565 million in 2030 from USD 334 million in 2025, growing at a CAGR of 9.6% during the forecast period. This market is growing as increased technological advancements continue to enhance the efficiency, sensitivity, and scalability of immunoassay-based research solutions. Innovations such as NGS integration, automated liquid handling systems, and high-throughput screening platforms enable faster and more accurate assay results. These advancements streamline workflows, reduce manual errors, and increase throughput, making IRS technologies more accessible and reliable for research and clinical applications. Moreover, the growing focus on personalized and precision medicine drives the demand for IRS solutions, as healthcare providers and researchers increasingly require tools that detect specific biomarkers and tailor treatments to individual patients. This shift toward targeted therapies fosters the development of particular assay kits & reagents designed to support companion diagnostics, therapeutic monitoring, and individualized treatment strategies. As a result, there is a rising need for immunoassay technologies that can deliver accurate, patient-centric data to guide clinical decisions and improve outcomes.

The sequencing technology segment held the largest share in the immune repertoire sequencing products market, by technology, during the forecast period.

In 2024, sequencing technology held the largest market within the IRS products market by technology. Sequencing technologies are the core enablers of immune repertoire



sequencing studies. Advances in NGS technologies have significantly lowered the cost per run while improving read lengths, throughput, and turnaround time—making sequencing more scalable and accessible across clinical and research settings. Moreover, the continuous innovation in platform technologies by key industry players has led to the commercialization of highly efficient, user-friendly sequencers that support a broad array of applications, including immuno-oncology, infectious disease profiling, and vaccine development. Thus, this central role, coupled with high adoption rates in both academic and commercial research environments, positions sequencing technology as the largest in the IRS product market.

Academic & research institutes held the largest market share in the immune repertoire sequencing products market, by end user, during the forecast period.

Academic & research institutes are the largest end users of IRS products, such as assay kits & reagents, instruments, and software. Universities and academic medical centers conduct many exploratory and hypothesis-driven studies that rely heavily on IRS technologies for immune profiling, biomarker discovery, and understanding disease mechanisms. The demand for assay kits, reagents, sequencing instruments, and bioinformatics software is consistently high in academia, where diverse research programs require flexible, scalable, and precise tools. Moreover, increased government and institutional funding for immunology, oncology, and infectious disease research further supports the widespread adoption of IRS technologies in academic settings.

The Asia Pacific is expected to be the fastest growing region in the immune repertoire sequencing market during the study period.

The Asia Pacific IRS market is projected to register the highest growth rate during the forecast period. This high growth is attributed to the growing emphasis on healthcare infrastructure development and increased investments in biomedical research. Governments across countries such as China, India, South Korea, and Japan allocate substantial funding to support life sciences and precision medicine initiatives, including the IRS. Additionally, increasing investments of key regional players, considering the enormous growth potential mainly due to the diverse population and low operational costs, is another key factor supporting the region's fastest growth during the forecast period.

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1—44%, Tier 2—32%, and Tier 3—24%



By Designation: (Managers)—45%, (CXOs, Directors)—30%, and (Executives)—25%

By Region: North America—40%, Europe—25%, Asia-Pacific—20%, Rest of the World—15%

List of Companies Profiled in the Report:

Illumina, Inc. (US)

Thermo Fisher Scientific Inc. (US)

PacBio (US)

Oxford Nanopore Technologies PLC (UK)

10X Genomics (US)

QIAGEN (Netherlands)

Agilent Technologies (US)

Danaher Corporation (US)

Takara Bio Inc. (Japan)

Adaptive Biotechnologies (US)

BGI Group (China)

Tecan Trading AG (Switzerland)

Azenta US Inc. (US)

Personalis, Inc. (US)

Creative Biolabs (US)



Celemics, Inc. (South Korea)

CellCarta (Canada)

iRepertoire, Inc. (US)

New England Biolabs (US)

Cerba Research (Belgium)

CeGat GmbH (Germany)

Element Biosciences (US)

Seqalis (Belgium)

Synbio Technologies (China)

MedGenome (US)

Enpicom (Netherlands)

Research Coverage:

This report provides a detailed picture of the global IRS market. It aims to estimate the market's size and future growth potential across different segments such as the product, service, application product-technology, product—end user, service—end user, and region. The report's scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the IRS market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, services, key strategies, partnerships, agreements, new product and service launches, mergers and acquisitions, and recent developments associated with the immune repertoire sequencing market. This report covers the competitive analysis of upcoming startups in the immune repertoire sequencing market ecosystem.

Reasons to Buy this Report:



The report will help market leaders and new entrants with information on the closest approximations of the revenue numbers for the overall immune repertoire sequencing market and its subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

Analysis of key drivers (Increasing technological advancements, growing focus on precision/personalized medicines, increasing use of IRS in organ transplantation), restraints (need for high capital investments), opportunities (integration of AI and ML in IRS), and challenges (variations in regulatory frameworks and international trade dynamics) influencing the growth of the immune repertoire sequencing market.

Product/ Service Development/Innovation: Detailed insights on upcoming technologies and new product and service launches in the immune repertoire sequencing market

Market Development: Comprehensive information about lucrative markets – the report analyses the immune repertoire sequencing market across varied regions.

Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the immune repertoire sequencing market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product and service offerings of leading players in the immune repertoire sequencing market.



Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
 - 1.3.1 SEGMENTS CONSIDERED & GEOGRAPHICAL SPREAD
 - 1.3.2 INCLUSIONS & EXCLUSIONS
 - 1.3.3 YEARS CONSIDERED
 - 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - 2.1.1 SECONDARY DATA
 - 2.1.1.1 Key objectives of secondary research
 - 2.1.2 PRIMARY DATA
 - 2.1.2.1 Breakdown of primaries
 - 2.1.2.2 Key objectives of primary research
- 2.2 MARKET ESTIMATION METHODOLOGY
 - 2.2.1 GLOBAL MARKET ESTIMATION
 - 2.2.1.1 Bottom-up approach
 - 2.2.1.2 Insights from primary experts
 - 2.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
- 2.3 MARKET GROWTH RATE PROJECTION
- 2.4 DATA TRIANGULATION
- 2.5 STUDY ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

- 4.1 IMMUNE REPERTOIRE SEQUENCING MARKET OVERVIEW
- 4.2 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT AND COUNTRY



- 4.3 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET SHARE, BY TECHNOLOGY, 2025 VS. 2030
- 4.4 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET SHARE, BY END USER, 2025
- 4.5 IMMUNE REPERTOIRE SEQUENCING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
 - 5.2.1 DRIVERS
 - 5.2.1.1 Increasing technological advancements
 - 5.2.1.2 Growing focus on personalized/precision medicines
- 5.2.1.3 Increasing use of immune repertoire sequencing in organ transplant monitoring
 - 5.2.1.4 Increasing applications in autoimmune disease research
 - 5.2.1.5 Rising focus on cancer immunotherapy research
 - 5.2.2 RESTRAINTS
 - 5.2.2.1 Need for high capital investments
 - 5.2.2.2 Limited clinical adoption and validation
 - 5.2.3 OPPORTUNITIES
 - 5.2.3.1 Integration of AI and ML into immune repertoire sequencing
 - 5.2.3.2 Increasing applications in vaccine development
 - 5.2.4 CHALLENGES
 - 5.2.4.1 Variations in regulatory frameworks and international trade dynamics
 - 5.2.4.2 Lack of workflow and data standardization
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.4 PRICING ANALYSIS
- 5.4.1 AVERAGE SELLING PRICE TREND OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS, BY KEY PLAYER, 2022–2024
- 5.4.2 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024
- 5.5 SUPPLY CHAIN ANALYSIS
- 5.6 VALUE CHAIN ANALYSIS
- 5.7 ECOSYSTEM ANALYSIS
 - 5.7.1 ROLE IN ECOSYSTEM
 - 5.7.1.1 Product providers
 - 5.7.1.2 Service providers



- 5.7.1.3 End users
- 5.7.1.4 Regulatory bodies

5.8 TECHNOLOGY ANALYSIS

- 5.8.1 KEY TECHNOLOGIES
 - 5.8.1.1 High-throughput sequencing
 - 5.8.1.2 Nanopore sequencing
 - 5.8.1.3 Single-molecule real-time (SMRT) sequencing
- 5.8.2 COMPLEMENTARY TECHNOLOGIES
 - 5.8.2.1 Bioinformatics and data analysis platforms
 - 5.8.2.2 Multiplex PCR
 - 5.8.2.3 5'RACE
- 5.8.3 ADJACENT TECHNOLOGIES
 - 5.8.3.1 Multi-omics integration
 - 5.8.3.2 Spatial genomics and transcriptomics
 - 5.8.3.3 Single-cell sequencing technologies
- 5.9 PATENT ANALYSIS
- 5.10 TRADE DATA ANALYSIS
 - 5.10.1 IMPORT DATA FOR HS CODE 3822, 2020?2024
 - 5.10.2 EXPORT DATA FOR HS CODE 3822, 2020?2024
- 5.11 KEY CONFERENCES & EVENTS, 2025-2026
- 5.12 REGULATORY ANALYSIS
- 5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 - 5.12.2 REGULATORY FRAMEWORK
 - 5.12.2.1 North America
 - 5.12.2.1.1 US
 - 5.12.2.1.2 Canada
 - 5.12.2.2 Europe
 - 5.12.2.2.1 UK
 - 5.12.2.3 Asia Pacific
 - 5.12.2.3.1 China
 - 5.12.2.3.2 Japan
 - 5.12.2.3.3 South Korea
 - 5.12.2.3.4 Australia
 - 5.12.2.3.5 India
 - 5.12.2.3.6 Rest of Asia Pacific
- 5.13 PORTER'S FIVE FORCES ANALYSIS
 - 5.13.1 THREAT OF NEW ENTRANTS
 - 5.13.2 THREAT OF SUBSTITUTES



- 5.13.3 BARGAINING POWER OF BUYERS
- 5.13.4 BARGAINING POWER OF SUPPLIERS
- 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
 - 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
 - 5.14.2 KEY BUYING CRITERIA
- 5.15 INVESTMENT & FUNDING SCENARIO
- 5.16 IMPACT OF AI/GEN AI ON IMMUNE REPERTOIRE SEQUENCING MARKET

6 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT

- 6.1 INTRODUCTION
- 6.2 ASSAY KITS & REAGENTS
 - 6.2.1 TCR KITS
 - 6.2.1.1 Human TCR kits
- 6.2.1.1.1 Increased demand for high-throughput TCR profiling in oncology and immunotherapy research to fuel market growth
 - 6.2.1.2 Mouse TCR kits
- 6.2.1.2.1 Rising demand for TCR profiling in preclinical studies and growing need for standardized workflows to drive segment
 - 6.2.2 BCR KITS
 - 6.2.2.1 Human BCR kits
- 6.2.2.1.1 Increasing demand for high-throughput profiling and rising focus on immunology research to fuel uptake
 - 6.2.2.2 Mouse BCR kits
- 6.2.2.2.1 High demand for antibody discovery and preclinical research to boost segment growth
 - 6.2.3 OTHER ASSAY KITS & REAGENTS
- 6.3 INSTRUMENTS & SOFTWARE
- 6.3.1 TECHNOLOGICAL ADVANCEMENTS IN TRANSLATIONAL RESEARCH AND COMPANION DIAGNOSTICS TO AUGMENT MARKET GROWTH

7 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY

- 7.1 INTRODUCTION
- 7.2 SEQUENCING TECHNOLOGIES
 - 7.2.1 BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES
- 7.2.1.1 Increasing adoption of TCR sequencing for inflammation-mediated diseases to support segment growth



7.2.2 SINGLE-CELL SEQUENCING TECHNOLOGIES

- 7.2.2.1 Need for integrative analysis of immune receptor repertoires and transcriptional states to spur market growth
- 7.3 LIBRARY PREPARATION TECHNOLOGIES
- 7.3.1 HIGH DEMAND FOR COST-EFFICIENT AND HIGH-THROUGHPUT IMMUNE REPERTOIRE PROFILING TO FUEL MARKET GROWTH
- 7.4 BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES
- 7.4.1 GROWING FOCUS ON RESEARCH TO DRIVE DEMAND FOR ADVANCED BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES

8 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW

- 8.1 INTRODUCTION
- 8.2 SEQUENCING SERVICES
- 8.2.1 RISING NEED FOR HIGH-RESOLUTION IMMUNE PROFILING IN CANCER AND AUTOIMMUNE DISEASES TO DRIVE MARKET
- 8.3 DATA ANALYSIS SERVICES
- 8.3.1 HIGH DEMAND FOR STANDARDIZED NGS DATA INTERPRETATION AND CROSS-SAMPLE COMPARABILITY TO DRIVE MARKET
- 8.4 PRE-SEQUENCING SERVICES
- 8.4.1 INCREASED REQUIREMENT FOR STANDARDIZED WORKFLOWS FOR ADDRESSING PCR BIAS TO AUGMENT MARKET GROWTH

9 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION

- 9.1 INTRODUCTION
- 9.2 RESEARCH APPLICATIONS
- 9.2.1 LOW SEQUENCING COSTS AND INCREASED NEED TO RESOLVE CELLULAR HETEROGENEITY AT HIGH RESOLUTION TO DRIVE MARKET
- 9.3 DRUG DISCOVERY & DEVELOPMENT
- 9.3.1 INCREASED NEED FOR TARGETED THERAPIES AND ADVANCEMENTS IN HIGH-THROUGHPUT SCREENING TO AID MARKET GROWTH
- 9.4 CLINICAL DIAGNOSTICS
- 9.4.1 GROWING DEMAND FOR EARLY DETECTION OF SUBCLINICAL CONDITIONS TO AID MARKET GROWTH

10 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER

10.1 INTRODUCTION



10.2 ACADEMIC & RESEARCH INSTITUTES

10.2.1 INCREASED FUNDING FOR IMMUNOLOGICAL RESEARCH AND IMMUNOGENOMICS TO DRIVE MARKET

10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

10.3.1 RISING FOCUS ON DRUG DISCOVERY AND THERAPEUTIC

DEVELOPMENT TO SUPPORT MARKET GROWTH

10.4 OTHER END USERS

11 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER

- 11.1 INTRODUCTION
- 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 11.2.1 NEED TO REDUCE IN-HOUSE INFRASTRUCTURE COSTS AND MEET SCALABILITY DEMANDS TO BOOST MARKET GROWTH
- 11.3 ACADEMIC & RESEARCH INSTITUTES
- 11.3.1 INCREASING FUNDING FOR GENOMIC RESEARCH AND GROWING DEMAND FOR COMPLEX DATA ANALYSIS TO AID MARKET GROWTH 11.4 OTHER END USERS

12 IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION

- 12.1 INTRODUCTION
- 12.2 NORTH AMERICA
 - 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 - 12.2.2 US
 - 12.2.2.1 US to dominate North American market during forecast period
 - 12.2.3 CANADA
- 12.2.3.1 Presence of advanced research facilities and favorable government-funded genomic studies to spur market growth
- **12.3 EUROPE**
 - 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 12.3.2 GERMANY
- 12.3.2.1 Technological advancements in RNA sequencing to fuel market growth 12.3.3 UK
- 12.3.3.1 Increased cross-sector partnerships and advancements in AI tools for large sequencing datasets to boost market growth
 - 12.3.4 FRANCE
- 12.3.4.1 Public-private collaborations and increased funding for advanced genomic infrastructure to aid market growth



12.3.5 ITALY

12.3.5.1 High investments in genomic research to drive market

12.3.6 SPAIN

12.3.6.1 Increased government investments in precision medicine, genomic medicine, and data science to propel market growth

12.3.7 REST OF EUROPE

12.4 ASIA PACIFIC

12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

12.4.2 CHINA

12.4.2.1 Rising incidence of chronic diseases and increasing collaborations among industry stakeholders to drive market

12.4.3 JAPAN

12.4.3.1 Increasing research on long-read and biomolecular sequencing to aid market growth

12.4.4 INDIA

12.4.4.1 Advancements in genomic research and focus on industry-academia collaborations to expedite market growth

12.4.5 SOUTH KOREA

12.4.5.1 Favorable government initiatives and investment in sequencing technologies to boost market growth

12.4.6 AUSTRALIA

12.4.6.1 Increased research funding and favorable government initiatives to drive market

12.4.7 REST OF ASIA PACIFIC

12.5 LATIN AMERICA

12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

12.5.2 BRAZIL

12.5.2.1 Supportive regulatory framework for biotechnology innovation to fuel market growth

12.5.3 MEXICO

12.5.3.1 High geriatric population and advancements in precision medicine research to support market growth

12.5.4 REST OF LATIN AMERICA

12.6 MIDDLE EAST

12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST

12.6.2 GCC COUNTRIES

12.6.2.1 Favorable government initiatives to drive drug development and clinical research

12.6.3 REST OF MIDDLE EAST



12.7 AFRICA

12.7.1 RISING GOVERNMENT FUNDING AND INCREASING INTERNATIONAL PARTNERSHIPS TO FAVOR MARKET GROWTH 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

- 13.1 INTRODUCTION
- 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022?2025
- 13.3 REVENUE ANALYSIS, 2022?2024
- 13.4 MARKET SHARE ANALYSIS, 2024
- 13.5 COMPANY VALUATION & FINANCIAL METRICS
 - 13.5.1 COMPANY VALUATION
 - 13.5.2 FINANCIAL METRICS
- 13.6 BRAND/PRODUCT COMPARISON
- 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
 - 13.7.1 STARS
 - 13.7.2 EMERGING LEADERS
 - 13.7.3 PERVASIVE PLAYERS
 - 13.7.4 PARTICIPANTS
 - 13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
 - 13.7.5.1 Company footprint
 - 13.7.5.2 Region footprint
 - 13.7.5.3 Product and service footprint
 - 13.7.5.4 Application footprint
- 13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
 - 13.8.1 PROGRESSIVE COMPANIES
 - 13.8.2 RESPONSIVE COMPANIES
 - 13.8.3 DYNAMIC COMPANIES
 - 13.8.4 STARTING BLOCKS
 - 13.8.5 COMPETITIVE BENCHMARKING
 - 13.8.5.1 Detailed list of key startups/SMEs
 - 13.8.5.2 Competitive benchmarking of key startups/SMEs
- 13.9 COMPETITIVE SCENARIO
 - 13.9.1 PRODUCT LAUNCHES/APPROVALS/UPGRADES
 - 13.9.2 DEALS
 - 13.9.3 EXPANSIONS

14 COMPANY PROFILES



14.1 KEY PLAYERS

- 14.1.1 ILLUMINA, INC.
 - 14.1.1.1 Business overview
 - 14.1.1.2 Products/Services/Solutions offered
 - 14.1.1.3 Recent developments
 - 14.1.1.3.1 Product launches/approvals/upgrades
 - 14.1.1.3.2 Deals
 - 14.1.1.3.3 Expansions
 - 14.1.1.4 MnM view
 - 14.1.1.4.1 Key strengths
 - 14.1.1.4.2 Strategic choices
 - 14.1.1.4.3 Weaknesses & competitive threats
- 14.1.2 THERMO FISHER SCIENTIFIC INC.
 - 14.1.2.1 Business overview
 - 14.1.2.2 Products/Services/Solutions offered
 - 14.1.2.3 Recent developments
 - 14.1.2.3.1 Product launches/approvals/upgrades
 - 14.1.2.3.2 Deals
 - 14.1.2.3.3 Expansions
 - 14.1.2.4 MnM view
 - 14.1.2.4.1 Key strengths
 - 14.1.2.4.2 Strategic choices
 - 14.1.2.4.3 Weaknesses & competitive threats
- 14.1.3 PACBIO
 - 14.1.3.1 Business overview
 - 14.1.3.2 Products/Services/Solutions offered
 - 14.1.3.3 Recent developments
 - 14.1.3.3.1 Product launches/approvals/upgrades
 - 14.1.3.3.2 Deals
 - 14.1.3.3.3 Expansions
 - 14.1.3.4 MnM view
 - 14.1.3.4.1 Key strengths
 - 14.1.3.4.2 Strategic choices
 - 14.1.3.4.3 Weaknesses & competitive threats
- 14.1.4 OXFORD NANOPORE TECHNOLOGIES PLC
 - 14.1.4.1 Business overview
 - 14.1.4.2 Products/Services/Solutions offered
 - 14.1.4.3 Recent developments



- 14.1.4.3.1 Product launches/approvals/upgrades
- 14.1.4.3.2 Deals
- 14.1.4.4 MnM view
 - 14.1.4.4.1 Key strengths
 - 14.1.4.4.2 Strategic choices
 - 14.1.4.4.3 Weaknesses & competitive threats
- 14.1.5 10X GENOMICS
 - 14.1.5.1 Business overview
 - 14.1.5.2 Products/Services/Solutions offered
 - 14.1.5.3 Recent developments
 - 14.1.5.3.1 Product launches/approvals/upgrades
 - 14.1.5.4 MnM view
 - 14.1.5.4.1 Key strengths
 - 14.1.5.4.2 Strategic choices
 - 14.1.5.4.3 Weaknesses & competitive threats
- 14.1.6 QIAGEN
 - 14.1.6.1 Business overview
 - 14.1.6.2 Products/Services/Solutions offered
 - 14.1.6.3 Recent developments
 - 14.1.6.3.1 Product launches/approvals/upgrades
 - 14.1.6.3.2 Deals
 - 14.1.6.3.3 Expansions
- 14.1.7 AGILENT TECHNOLOGIES
 - 14.1.7.1 Business overview
 - 14.1.7.2 Products/Services/Solutions offered
 - 14.1.7.3 Recent developments
 - 14.1.7.3.1 Deals
 - 14.1.7.3.2 Expansions
- 14.1.8 DANAHER CORPORATION
 - 14.1.8.1 Business overview
 - 14.1.8.2 Products/Services/Solutions offered
 - 14.1.8.3 Recent developments
 - 14.1.8.3.1 Deals
- 14.1.9 TAKARA BIO INC.
 - 14.1.9.1 Business overview
 - 14.1.9.2 Products/Services/Solutions offered
- 14.1.9.3 Recent developments
 - 14.1.9.3.1 Deals
- 14.1.10 ADAPTIVE BIOTECHNOLOGIES



- 14.1.10.1 Business overview
- 14.1.10.2 Products/Services/Solutions offered
- 14.1.11 BGI GROUP
 - 14.1.11.1 Business overview
 - 14.1.11.2 Products/Services/Solutions offered
 - 14.1.11.3 Recent developments
 - 14.1.11.3.1 Product launches/approvals/upgrades
 - 14.1.11.3.2 Deals
 - 14.1.11.3.3 Other developments
- 14.1.12 TECAN TRADING AG
 - 14.1.12.1 Business overview
 - 14.1.12.2 Products/Services/Solutions offered
 - 14.1.12.3 Recent developments
 - 14.1.12.3.1 Deals
- 14.1.13 AZENTA US INC.
 - 14.1.13.1 Business overview
- 14.1.13.2 Products/Services/Solutions offered
- 14.1.14 PERSONALIS, INC.
 - 14.1.14.1 Business overview
 - 14.1.14.2 Products/Services/Solutions offered
 - 14.1.14.3 Recent developments
 - 14.1.14.3.1 Deals
 - 14.1.14.3.2 Other developments
- 14.1.15 CREATIVE BIOLABS
 - 14.1.15.1 Business overview
 - 14.1.15.2 Products/Services/Solutions offered
- 14.2 OTHER PLAYERS
 - 14.2.1 CELEMICS, INC.
 - 14.2.2 CELLCARTA
 - 14.2.3 IREPERTOIRE, INC.
 - 14.2.4 NEW ENGLAND BIOLABS
 - 14.2.5 CERBA RESEARCH
 - 14.2.6 CEGAT GMBH
 - 14.2.7 ELEMENT BIOSCIENCES
 - 14.2.8 **SEQALIS**
 - 14.2.9 SYNBIO TECHNOLOGIES
 - 14.2.10 MEDGENOME
 - 14.2.11 ENPICOM



15 APPENDIX

- 15.1 DISCUSSION GUIDE
- 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 15.3 CUSTOMIZATION OPTIONS
- 15.4 RELATED REPORTS
- 15.5 AUTHOR DETAILS



List Of Tables

LIST OF TABLES

TABLE 1 IMMUNE REPERTOIRE SEQUENCING MARKET: INCLUSIONS & EXCLUSIONS

TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS

TABLE 3 IMMUNE REPERTOIRE SEQUENCING MARKET: RISK ANALYSIS

TABLE 4 IMMUNE REPERTOIRE SEQUENCING MARKET: IMPACT ANALYSIS

TABLE 5 AVERAGE SELLING PRICE TREND OF IMMUNE REPERTOIRE

SEQUENCING PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)

TABLE 6 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024 (USD)

TABLE 7 IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT PROVIDERS

TABLE 8 IMMUNE REPERTOIRE SEQUENCING MARKET: SERVICE PROVIDERS

TABLE 9 IMMUNE REPERTOIRE SEQUENCING MARKET: END USERS

TABLE 10 IMMUNE REPERTOIRE SEQUENCING MARKET: REGULATORY BODIES

TABLE 11 INNOVATIONS AND PATENT REGISTRATIONS, 2024–2025

TABLE 12 IMPORT DATA FOR HS CODE 3822, BY REGION, 2020?2024 (USD)

TABLE 13 EXPORT DATA FOR HS CODE 3822, BY REGION, 2020?2024 (USD)

TABLE 14 IMMUNE REPERTOIRE SEQUENCING MARKET: LIST OF KEY

CONFERENCES & EVENTS, JANUARY 2025-DECEMBER 2026

TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES. AND OTHER ORGANIZATIONS

TABLE 19 IMMUNE REPERTOIRE SEQUENCING MARKET: PORTER'S FIVE FORCES

TABLE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
TABLE 21 KEY BUYING CRITERIA FOR MAJOR END USERS (PRODUCTS
MARKET)

TABLE 22 KEY BUYING CRITERIA FOR MAJOR END USERS (SERVICES MARKET) TABLE 23 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 24 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR



ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)
TABLE 25 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR
ASSAY KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 26 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS
MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 27 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) TABLE 28 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 29 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 30 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 31 TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 32 TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 33 NORTH AMERICA: TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 34 EUROPE: TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) TABLE 35 ASIA PACIFIC: TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 36 LATIN AMERICA: TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 37 MIDDLE EAST: TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 38 HUMAN TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) TABLE 39 NORTH AMERICA: HUMAN TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 40 EUROPE: HUMAN TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 41 ASIA PACIFIC: HUMAN TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 42 LATIN AMERICA: HUMAN TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 43 MIDDLE EAST: HUMAN TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 44 MOUSE TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)



TABLE 45 NORTH AMERICA: MOUSE TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 46 EUROPE: MOUSE TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 47 ASIA PACIFIC: MOUSE TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 48 LATIN AMERICA: MOUSE TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 49 MIDDLE EAST: MOUSE TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 50 BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 51 BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 52 NORTH AMERICA: BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 53 EUROPE: BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) TABLE 54 ASIA PACIFIC: BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 55 LATIN AMERICA: BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 56 MIDDLE EAST: BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 57 HUMAN BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) TABLE 58 NORTH AMERICA: HUMAN BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 59 EUROPE: HUMAN BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 60 ASIA PACIFIC: HUMAN BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 61 LATIN AMERICA: HUMAN BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 62 MIDDLE EAST: HUMAN BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 63 MOUSE BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) TABLE 64 NORTH AMERICA: MOUSE BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 65 EUROPE: MOUSE BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 66 ASIA PACIFIC: MOUSE BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)



TABLE 67 LATIN AMERICA: MOUSE BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 68 MIDDLE EAST: MOUSE BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 69 OTHER ASSAY KITS & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 70 NORTH AMERICA: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 71 EUROPE: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 72 ASIA PACIFIC: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 73 LATIN AMERICA: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 74 MIDDLE EAST: OTHER ASSAY KITS & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 75 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY REGION, 2023–2030 (USD MILLION)
TABLE 76 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 77 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) TABLE 78 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 79 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 80 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY REGION, 2023–2030 (USD MILLION)

TABLE 81 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 82 SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 83 SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 84 NORTH AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY



COUNTRY, 2023-2030 (USD MILLION)

TABLE 85 EUROPE: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 86 ASIA PACIFIC: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 87 LATIN AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 88 MIDDLE EAST: SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 89 BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 90 NORTH AMERICA: BULK SEQUENCING (MULTI-CELL SEQUENCING)

TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 91 EUROPE: BULK SEQUENCING (MULTI-CELL SEQUENCING)

TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 92 ASIA PACIFIC: BULK SEQUENCING (MULTI-CELL SEQUENCING)

TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)

TABLE 93 LATIN AMERICA: BULK SEQUENCING (MULTI-CELL SEQUENCING)

TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)

TABLE 94 MIDDLE EAST: BULK SEQUENCING (MULTI-CELL SEQUENCING)

TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 95 SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 96 NORTH AMERICA: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 97 EUROPE: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 98 ASIA PACIFIC: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 99 LATIN AMERICA: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 100 MIDDLE EAST: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 101 LIBRARY PREPARATION TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 102 NORTH AMERICA: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 103 EUROPE: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)



TABLE 104 ASIA PACIFIC: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 105 LATIN AMERICA: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 106 MIDDLE EAST: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 107 BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 108 NORTH AMERICA: BIOINFORMATICS & DATA ANALYSIS

TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 109 EUROPE: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 110 ASIA PACIFIC: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 111 LATIN AMERICA: BIOINFORMATICS & DATA ANALYSIS

TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 112 MIDDLE EAST: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 113 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 114 SEQUENCING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 115 NORTH AMERICA: SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 116 EUROPE: SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 117 ASIA PACIFIC: SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 118 LATIN AMERICA: SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 119 MIDDLE EAST: SEQUENCING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 120 DATA ANALYSIS SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 121 NORTH AMERICA: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 122 EUROPE: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 123 ASIA PACIFIC: DATA ANALYSIS SERVICES MARKET, BY COUNTRY,



2023-2030 (USD MILLION)

TABLE 124 LATIN AMERICA: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 125 MIDDLE EAST: DATA ANALYSIS SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 126 PRE-SEQUENCING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 127 NORTH AMERICA: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 128 EUROPE: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 129 ASIA PACIFIC: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 130 LATIN AMERICA: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 131 MIDDLE EAST: PRE-SEQUENCING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 132 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 133 IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 134 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) TABLE 135 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 136 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 137 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 138 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 139 IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION)

TABLE 140 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD

MILLION)

TABLE 141 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 142 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET FOR



DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) TABLE 143 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) TABLE 144 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION) TABLE 145 IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION)

TABLE 146 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 147 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 148 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 149 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 150 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION)

TABLE 151 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 152 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) TABLE 153 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 154 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 155 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 156 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 157 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)

TABLE 158 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)



USER, 2023-2030 (USD MILLION)

TABLE 159 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 160 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 161 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 162 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 163 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 164 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 165 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 166 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 168 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 169 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 170 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END

TABLE 171 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 172 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 173 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 174 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES



MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 175 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 176 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 177 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) TABLE 178 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 179 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 180 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 181 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 182 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)

TABLE 183 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 184 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 185 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 186 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 187 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 188 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 189 IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION, 2023–2030 (USD MILLION)



TABLE 190 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 191 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 192 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) TABLE 193 NORTH AMERICA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 194 NORTH AMERICA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 195 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 196 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 197 NORTH AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 198 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 199 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 200 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 201 NORTH AMERICA: KEY MACROECONOMIC INDICATORS

TABLE 202 US: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 203 US: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 204 US: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 205 US: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)

TABLE 206 US: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 207 US: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 208 US: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 209 US: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 210 US: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)



TABLE 211 US: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 212 CANADA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 213 CANADA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 214 CANADA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 215 CANADA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 216 CANADA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 217 CANADA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 218 CANADA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 219 CANADA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 220 CANADA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 221 CANADA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 222 EUROPE: KEY MACROECONOMIC INDICATORS

TABLE 223 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY

COUNTRY, 2023–2030 (USD MILLION)

TABLE 224 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 225 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 226 EUROPE: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 227 EUROPE: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 228 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 229 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 230 EUROPE: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 231 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 232 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)



TABLE 233 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 234 GERMANY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 235 GERMANY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS

MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 236 GERMANY: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 237 GERMANY: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 238 GERMANY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 239 GERMANY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 240 GERMANY: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 241 GERMANY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 242 GERMANY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 243 GERMANY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 244 UK: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 245 UK: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 246 UK: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 247 UK: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 248 UK: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 249 UK: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 250 UK: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 251 UK: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 252 UK: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 253 UK: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 254 FRANCE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY



PRODUCT, 2023–2030 (USD MILLION)

TABLE 255 FRANCE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET

FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 256 FRANCE: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 257 FRANCE: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 258 FRANCE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,

BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 259 FRANCE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 260 FRANCE: SEQUENCING TECHNOLOGIES MARKET, BY TYPE,

2023-2030 (USD MILLION)

TABLE 261 FRANCE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY

APPLICATION, 2023–2030 (USD MILLION)

TABLE 262 FRANCE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,

BY END USER, 2023–2030 (USD MILLION)

TABLE 263 FRANCE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET,

BY END USER, 2023–2030 (USD MILLION)

TABLE 264 ITALY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,

2023-2030 (USD MILLION)

TABLE 265 ITALY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET

FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 266 ITALY: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 267 ITALY: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 268 ITALY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY

WORKFLOW, 2023–2030 (USD MILLION)

TABLE 269 ITALY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY

TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 270 ITALY: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030

(USD MILLION)

TABLE 271 ITALY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY

APPLICATION, 2023–2030 (USD MILLION)

TABLE 272 ITALY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY

END USER, 2023–2030 (USD MILLION)

TABLE 273 ITALY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY

END USER, 2023-2030 (USD MILLION)

TABLE 274 SPAIN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT,

2023-2030 (USD MILLION)

TABLE 275 SPAIN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET

FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)



TABLE 276 SPAIN: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)

TABLE 277 SPAIN: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 278 SPAIN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY

WORKFLOW, 2023-2030 (USD MILLION)

TABLE 279 SPAIN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,

BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 280 SPAIN: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030

(USD MILLION)

TABLE 281 SPAIN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY

APPLICATION, 2023–2030 (USD MILLION)

TABLE 282 SPAIN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET,

BY END USER, 2023–2030 (USD MILLION)

TABLE 283 SPAIN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY

END USER, 2023–2030 (USD MILLION)

TABLE 284 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY

PRODUCT, 2023–2030 (USD MILLION)

TABLE 285 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS

MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 286 REST OF EUROPE: TCR KITS MARKET, BY TYPE, 2023–2030 (USD

MILLION)

TABLE 287 REST OF EUROPE: BCR KITS MARKET, BY TYPE, 2023–2030 (USD

MILLION)

TABLE 288 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES

MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)

TABLE 289 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS

MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 290 REST OF EUROPE: SEQUENCING TECHNOLOGIES MARKET, BY

TYPE, 2023–2030 (USD MILLION)

TABLE 291 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY

APPLICATION, 2023–2030 (USD MILLION)

TABLE 292 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS

MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 293 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES

MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 294 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY

COUNTRY, 2023-2030 (USD MILLION)

TABLE 295 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY

PRODUCT, 2023-2030 (USD MILLION)

TABLE 296 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS



MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) TABLE 297 ASIA PACIFIC: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 298 ASIA PACIFIC: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 299 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 300 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

...



List Of Figures

LIST OF FIGURES

FIGURE 1 IMMUNE REPERTOIRE SEQUENCING MARKET: SEGMENTS CONSIDERED & GEOGRAPHICAL SPREAD

FIGURE 2 IMMUNE REPERTOIRE SEQUENCING MARKET: YEARS CONSIDERED

FIGURE 3 IMMUNE REPERTOIRE SEQUENCING MARKET: RESEARCH DESIGN

FIGURE 4 IMMUNE REPERTOIRE SEQUENCING MARKET: BREAKDOWN OF PRIMARIES

FIGURE 5 IMMUNE REPERTOIRE SEQUENCING MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2024)

FIGURE 6 GLOBAL PRODUCTS MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (2024)

FIGURE 7 GLOBAL SERVICES MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (2024)

FIGURE 8 IMMUNE REPERTOIRE SEQUENCING MARKET SIZE VALIDATION FROM PRIMARY SOURCES

FIGURE 9 IMMUNE REPERTOIRE SEQUENCING MARKET: TOP-DOWN APPROACH

FIGURE 10 IMMUNE REPERTOIRE SEQUENCING MARKET: CAGR PROJECTIONS FIGURE 11 DATA TRIANGULATION METHODOLOGY

FIGURE 12 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)

FIGURE 13 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)

FIGURE 14 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2025 VS. 2030 (USD MILLION)

FIGURE 15 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)

FIGURE 16 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)

FIGURE 17 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)

FIGURE 18 IMMUNE REPERTOIRE SEQUENCING MARKET: REGIONAL SNAPSHOT

FIGURE 19 INCREASING ADOPTION OF PERSONALIZED MEDICINES AND RISING FOCUS ON GENOMIC RESEARCH TO DRIVE MARKET

FIGURE 20 US AND ASSAY KITS & REAGENTS DOMINATED NORTH AMERICAN



MARKET IN 2024

FIGURE 21 SEQUENCING TECHNOLOGIES TO ACCOUNT FOR LARGEST MARKET SHARE IN 2030

FIGURE 22 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO COMMAND LARGEST END USER MARKET SHARE IN 2025

FIGURE 23 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030

FIGURE 24 IMMUNE REPERTOIRE SEQUENCING MARKET: DRIVERS,

RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 25 IMMUNE REPERTOIRE SEQUENCING MARKET:

TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

FIGURE 26 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS, BY KEY PLAYER (2024)

FIGURE 27 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024 (USD)

FIGURE 28 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: SUPPLY CHAIN ANALYSIS

FIGURE 29 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: VALUE CHAIN ANALYSIS

FIGURE 30 IMMUNE REPERTOIRE SEQUENCING MARKET: ECOSYSTEM ANALYSIS

FIGURE 31 PATENT APPLICATIONS FOR IMMUNE REPERTOIRE SEQUENCING (JANUARY 2015-DECEMBER 2024)

FIGURE 32 IMMUNE REPERTOIRE SEQUENCING MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FIGURE 34 KEY BUYING CRITERIA FOR MAJOR END USERS (PRODUCTS MARKET)

FIGURE 35 KEY BUYING CRITERIA FOR MAJOR END USERS (SERVICES MARKET)

FIGURE 36 FUNDING AND NUMBER OF PROJECTS AND SUB-PROJECTS BY NATIONAL INSTITUTES OF HEALTH, 2021–2025

FIGURE 37 IMPACT OF AI/GEN AI ON IMMUNE REPERTOIRE SEQUENCING MARKET

FIGURE 38 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET SNAPSHOT

FIGURE 39 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET SNAPSHOT

FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET (2022?2024)



FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET (2022?2024)

FIGURE 42 MARKET SHARE ANALYSIS OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, 2024

FIGURE 43 MARKET SHARE ANALYSIS OF IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, 2024

FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS

FIGURE 45 EV/EBITDA OF KEY PLAYERS

FIGURE 46 IMMUNE REPERTOIRE SEQUENCING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS

FIGURE 47 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY

EVALUATION MATRIX (KEY PLAYERS), 2024

FIGURE 48 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY FOOTPRINT

FIGURE 49 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY

EVALUATION MATRIX (STARTUPS/SMES), 2024

FIGURE 50 ILLUMINA, INC.: COMPANY SNAPSHOT

FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

FIGURE 52 PACBIO: COMPANY SNAPSHOT

FIGURE 53 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT

FIGURE 54 10X GENOMICS: COMPANY SNAPSHOT

FIGURE 55 QIAGEN: COMPANY SNAPSHOT

FIGURE 56 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT

FIGURE 57 DANAHER CORPORATION: COMPANY SNAPSHOT

FIGURE 58 TAKARA BIO INC.: COMPANY SNAPSHOT

FIGURE 59 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT

FIGURE 60 TECAN TRADING AG: COMPANY SNAPSHOT

FIGURE 61 AZENTA US INC.: COMPANY SNAPSHOT

FIGURE 62 PERSONALIS, INC.: COMPANY SNAPSHOT



I would like to order

Product name: Immune Repertoire Sequencing Market by Product (Instrument, Software, Assay Kit &

Reagent (TCR, BCR Kit)), Technology (Sequencing, Bioinformatics), Service (Data Analysis), Application (Research, Drug Discovery & Development) - Global Forecast to

2030

Product link: https://marketpublishers.com/r/I5FD02B1951EEN.html

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/l5FD02B1951EEN.html